IL1A and macrophage activation syndrome: IL-1 inhibitors demonstrate favorable safety and efficacy in managing autoinflammatory conditions such as Kawasaki disease, idiopathic recurrent pericarditis, Behçet’s disease, monogenic autoinflammatory diseases (AIDs), undifferentiated AIDs, chronic non-bacterial osteomyelitis, macrophage activation syndrome, and febrile infection-related epilepsy (Maniscalco et al., 2020; Del Giudice et al., 2022; Alexeeva et al., 2023).